FUNDAMENTAL AND CLINICAL STUDIES OF BRL 28500 (CLAVULANIC ACID-TICARCILLIN) IN THE SURGICAL FIELD AND THERAPEUTIC EFFICACY OF CLAVULANIC ACID ON EXPERIMENTAL MIXED INFECTION

• Published in: CHEMOTHERAPY Vol. 34; no. Supplement4; pp. 806 - 817
• Main Authors: ISHIKAWA, SHU, YURA, JIRO, SHINAGAWA, NAGAO, TACHI, YOSHIMASA, KOBE, AKIO, SHIBATA, YOSHITAKA, MASHITA, KEIJI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1986
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.34.Supplement4_806

Fundamental and clinical studies of BRL 28500, a new combined antibiotic consisting of one part clavulanic acid (CVA) plus 15 parts ticarcillin (TIPC), were performed in the surgical field, and the following results were obtained. 1) Antibacterial activity: Against 77 strains of S. aureus, E. coli, Klebsiella and P. aeruginosa, antibacterial activities of BRL 28500 and TIPC were examined. BRL 28500 showed superior activity to TIPC against S. aureus, E. coli and Klebsiella, but similar to it against P. aeruginosa. 2) Bile excretion: On three patients, bile excretion of BRL 28500 were examined. Bile levels of CVA were less than those of TIPC. On the patients with detection of bacteria in the bile, bile levels of TIPC after administration of BRL 28500 was higher than those of TIPC. 3) Clinical results: BRL 28500 administered to 7 patients with surgical infections and the clinical results were excellent in 3 cases, good in 3 and poor in one. Overall efficacy rate was 85. 7%. No side effect and no adverse reaction on laboratory findings could be found. 4) On the therapy for experimental mixed infection in rabbits infected with E. coli and B. fragilis, the significance of combined administration of TIPC with CVA was recognized, and furthermore a general idea of indirect pathogenicity was confirmed.